[go: up one dir, main page]

SG11202105029WA - Novel folr1 specific binding proteins for cancer diagnosis and treatment - Google Patents

Novel folr1 specific binding proteins for cancer diagnosis and treatment

Info

Publication number
SG11202105029WA
SG11202105029WA SG11202105029WA SG11202105029WA SG11202105029WA SG 11202105029W A SG11202105029W A SG 11202105029WA SG 11202105029W A SG11202105029W A SG 11202105029WA SG 11202105029W A SG11202105029W A SG 11202105029WA SG 11202105029W A SG11202105029W A SG 11202105029WA
Authority
SG
Singapore
Prior art keywords
treatment
specific binding
binding proteins
cancer diagnosis
novel folr1
Prior art date
Application number
SG11202105029WA
Inventor
Erik Fiedler
Ulrich Haupts
Manja Gloser
Eva Bosse-Doenecke
Original Assignee
Navigo Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins Gmbh filed Critical Navigo Proteins Gmbh
Publication of SG11202105029WA publication Critical patent/SG11202105029WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202105029WA 2018-12-18 2019-12-17 Novel folr1 specific binding proteins for cancer diagnosis and treatment SG11202105029WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18213661 2018-12-18
EP19160572 2019-03-04
PCT/EP2019/085596 WO2020127224A1 (en) 2018-12-18 2019-12-17 Novel folr1 specific binding proteins for cancer diagnosis and treatment

Publications (1)

Publication Number Publication Date
SG11202105029WA true SG11202105029WA (en) 2021-06-29

Family

ID=68848307

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105029WA SG11202105029WA (en) 2018-12-18 2019-12-17 Novel folr1 specific binding proteins for cancer diagnosis and treatment

Country Status (14)

Country Link
US (1) US20220127312A1 (en)
EP (1) EP3898659A1 (en)
JP (2) JP2022514860A (en)
KR (1) KR20210104106A (en)
CN (1) CN113166217B (en)
AU (1) AU2019409572B2 (en)
BR (1) BR112021009912A2 (en)
CA (1) CA3123986A1 (en)
IL (1) IL284097B1 (en)
MA (1) MA54501A (en)
MX (1) MX2021007283A (en)
PH (1) PH12021551174A1 (en)
SG (1) SG11202105029WA (en)
WO (1) WO2020127224A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526526A (en) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH Target compounds for site-specific coupling of chemical moieties containing peptide linkers
WO2022098743A1 (en) * 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10324447A1 (en) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
KR101436222B1 (en) * 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
EP3253785B1 (en) * 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
WO2017013136A1 (en) * 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
US20180273636A1 (en) * 2015-07-20 2018-09-27 Navigo Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
CN107793471B (en) * 2017-07-26 2020-08-11 中国药科大学 Folate receptor alpha specific binding peptide 4 and application thereof

Also Published As

Publication number Publication date
CN113166217B (en) 2025-02-07
AU2019409572A1 (en) 2021-06-10
CN113166217A (en) 2021-07-23
CA3123986A1 (en) 2020-06-25
IL284097A (en) 2021-08-31
IL284097B1 (en) 2025-06-01
JP2022514860A (en) 2022-02-16
KR20210104106A (en) 2021-08-24
US20220127312A1 (en) 2022-04-28
EP3898659A1 (en) 2021-10-27
PH12021551174A1 (en) 2021-10-25
MX2021007283A (en) 2021-07-15
JP2023157023A (en) 2023-10-25
JP7608538B2 (en) 2025-01-06
BR112021009912A2 (en) 2022-01-18
WO2020127224A1 (en) 2020-06-25
AU2019409572B2 (en) 2022-11-24
MA54501A (en) 2021-10-27

Similar Documents

Publication Publication Date Title
RS66693B1 (en) Dll3/cd3 binding proteins for cancer treatment
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL274246A (en) Diagnostic and therapeutic methods for cancer
IL273071A (en) Diagnostic and therapeutic methods for cancer
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
IL277861A (en) Axl-specific antibodies for cancer treatment
ZA202108843B (en) Novel psma specific binding proteins for cancer diagnosis and treatment
IL281441B (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
IL285541A (en) Antibodies that bind tumor tissue for diagnosis and therapy
IL256000A (en) Quantifying her 2 protein for optimal cancer therapy
EP3303402A4 (en) Antibodies against glypican-3 and their uses in cancer diagnosis and treatment
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
IL274008A (en) Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
IL274007A (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
IL281439A (en) Combination therapy for treating blood cancer
IL284097A (en) FOLR1 binding proteins for cancer diagnosis and treatment
HK40060349A (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
GB201810635D0 (en) Peptides and cancer treatment
HK40051005A (en) Antibodies that bind tumor tissue for diagnosis and therapy
HK40058955A (en) Methods for determining treatment for cancer patients
HK40038634A (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
HK40020454B (en) Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same
HK40046198A (en) Axl-specific antibodies for cancer treatment